Allergy Therapeutics (LSE:AGY) OCF Margin %: -32.40% (As of Dec. 2025)


What is Allergy Therapeutics OCF Margin %?

Allergy Therapeutics LSE:AGY OCF Margin % is -32.40% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 959 Drug Manufacturers companies, Allergy Therapeutics ranks worse than 90.72% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Allergy Therapeutics's Cash Flow from Operations for the six months ended in Dec. 2025 was £-11.76 Mil. Allergy Therapeutics's Revenue for the six months ended in Dec. 2025 was £36.28 Mil. Therefore, Allergy Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was -32.40%.

As of today, Allergy Therapeutics's current OCF Yield % is -7.34%.

The historical rank and industry rank for Allergy Therapeutics's OCF Margin % or its related term are showing as below:

LSE:AGY' s OCF Margin % Range Over the Past 10 Years
Min: -58.22   Med: -12.4   Max: 15.96
Current: -56.77

During the past 13 years, the highest OCF Margin % of Allergy Therapeutics was 15.96%. The lowest was -58.22%. And the median was -12.40%.

LSE:AGY's OCF Margin % is ranked worse than
90.72% of 959 companies
in the Drug Manufacturers industry
Industry Median: 9.94 vs LSE:AGY: -56.77

Allergy Therapeutics OCF Margin % Related Terms

Allergy Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Allergy Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allergy Therapeutics OCF Margin % Chart

Allergy Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.18 -19.24 -48.47 -58.22 -51.07

Allergy Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.09 -98.78 -21.58 -98.82 -32.40

LSE:AGY vs ZTS, UTHR, VTRS: OCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allergy Therapeutics OCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's OCF Margin % falls into.


Allergy Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Allergy Therapeutics's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-28.109/55.044
=-51.07 %

Allergy Therapeutics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-11.756/36.28
=-32.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -32.40% mean?
Allergy Therapeutics (LSE:AGY) has a OCF Margin % of -32.40% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Allergy Therapeutics and its competitors. According to the industry distribution chart, Allergy Therapeutics ranks #870 out of 959 companies in the Drug Manufacturers industry, placing it in the top 90.7%.
Is Allergy Therapeutics' OCF Margin % too high?
Allergy Therapeutics' current OCF Margin % is -32.40%. Based on the distribution chart, Allergy Therapeutics ranks #870 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Allergy Therapeutics' OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #870 out of 959 companies for OCF Margin %. This places Allergy Therapeutics in the lower half of its industry. The industry median OCF Margin % is 9.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Allergy Therapeutics and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allergy Therapeutics's current OCF Margin % is -32.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.07 — trading 133.3% above its estimated fair value. The current OCF Margin % is -32.40%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current OCF Margin % is -32.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allergy Therapeutics Business Description

Other Exchanges AGYTF:USAHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).